BioProcess Technology Consultants, Inc. Launches BPTC.com and New Corporate Identity
“BPTC's updated corporate identity reflects our dedication to assisting clients during all phases of product development, and emphasizes our fully integrated team,” said Howard L. Levine, Ph.D., BPTC President. “We offer committed, knowledgeable consultants with hands-on experience and technical expertise who understand the challenges of biopharmaceutical product development. They can provide customized solutions to meet our client’s objectives every step of the way, ‘from clone to commercial,’” added Dr. Levine.
Julia Dishman, Manager, Sales and Marketing, said, “Our energetic new logo reflects the dynamic nature of the biopharmaceutical industry and symbolizes the integration of the BPTC team with its clients’ culture, becoming a true partner in the development of their products. It also emphasizes how BPTC helps clients achieve their key milestones quickly and efficiently.” Ms. Dishman added, “Our newly redesigned website incorporates modern navigational tools and a simple, concise layout to make it easier for people to find the information they need and to help them move forward confidently.”
BPTC is formally introducing the new identity at the IBC 2011 Biopharmaceutical Development & Production Week, March 14-18, in Bellevue, Washington where Dr. Levine will be chairing a Strategic Discussion Forum on Phase Appropriate Approaches to Early Product Development and chairing a session on The Evolution of Downstream Processing. Dr. Wolf Noe, Senior Consultant, will be speaking on the Design of Flexible Facilities and also participating in the Strategic Discussion Forum. Patricia Seymour, Senior Consultant, will also be speaking about Technology Transfer & Outsourcing of CMC Activities for the Manufacture of Monoclonal Antibodies.
In celebration of the launch of the new website, the Company will offer its report, “The Development of Therapeutic Monoclonal Antibodies,” at the discounted price of $995 through May 18, 2011. This report provides invaluable information for the successful development of therapeutic monoclonal antibody products from discovery through first-in-man clinical trials and gives an overview of the strategic and regulatory considerations for late-stage development and commercialization of these products. Copies of the report may be ordered directly from BPTC’s website at http://www.bptc.com/specialreports.php.
About BioProcess Technology Consultants
Founded in 1994, BPTC is the recognized worldwide leader in biologics CMC consulting, providing a full range of technical, regulatory, and strategic assistance to biopharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. The company works with clients to find solutions to the challenges of producing biopharmaceutical supply from clone to commercial®. BPTC specializes in helping develop manufacturing processes and strategies and assists in developing product discovery and process development programs that enhance the overall value of client companies. BPTC also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more information about BPTC, visit http://www.bptc.com and follow the Company on Twitter at bptcGlobal or LinkedIn at http://www.linkedin.com/company/bioprocess-technology-consultants-inc.